Yifei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yifei Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Feng Li
School of traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
4 shared publications - Zehan Zhang
School of traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
3 shared publications - Qingqian Yu
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
2 shared publications - Yan Liu
School of traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Bijuan Lan
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
1 shared publication - Fafeng Cheng
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Springer Nature in Molecular Medicine
Circadian chaos: the role of bile acids in chronic stress-induced insomnia
- 31 August 2026
- Published by Springer Nature in Molecular Medicine
Open AccessCircadian chaos: the role of bile acids in chronic stress-induced insomnia
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Mitochondria-Related Genome-Wide Mendelian Randomization Identifies Putatively Genes for Chronic Fatigue
Chronic fatigue is a debilitating symptom linked to mitochondrial dysfunction which lacks comprehensive genetic insights. This study aims to investigate mitochondrial-related genes associated with chronic fatigue and explores therapeutic targets. We conducted summary-data-based Mendelian randomization (SMR) and Bayesian colocalization analyses using blood eQTL data (n = 31,684) and fatigue GWAS data (n = 449,019). Mitochondrial-related genes were sourced from MitoCarta3.0. Two-sample Mendelian randomization (TSMR) analysis and gene expression detection in rat models of fatigue were employed to enhance the robustness of our findings. Drug-gene interactions were screened via Drug SIGnatures (DSigDB) database and DrugBank database, followed by molecular docking and phenome-wide association study (PheWAS) for safety and pleiotropic effects evaluation. SMR identified nine mitochondrial-related genes, with AKAP10 (OR = 1.012) and MTHFD1L (OR = 1.027) showing robust colocalization and causal links to chronic fatigue. TSMR analysis also indicated significant causal relationships of AKAP10 (OR = 1.017, 95% CI = 1.011-1.023, p = 8.15e-08) and MTHFD1L (OR = 1.046, 95% CI = 1.002-1.091, p = 0.041) with chronic fatigue. Consistently, in fatigue model rats, the expression levels of Akap10 and Mthfd1l were significantly upregulated in both hippocampal and quadriceps tissues (p = 0.021, p = 0.003, p = 0.027, p = 0.001, respectively). Molecular docking revealed strong binding affinities (below -7.0 kcal/mol) between AKAP10, MTHFD1L and repurposed drugs (e.g., irinotecan, digoxin). PheWAS indicated that both AKAP10 and MTHFD1L exhibit no significant associations with other traits at the gene level. Mitochondria-related genes AKAP10 and MTHFD1L are promising targets for the treatment of chronic fatigue. Structural modification of existing drugs targeting these genes may lead to novel therapeutic approaches, which warrants further molecular and pharmacological validation to confirm their potential application in fatigue treatment.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1)
Mitochondria-Related Genome-Wide Mendelian Randomization Identifies Putatively Genes for Chronic Fatigue
Chronic fatigue is a debilitating symptom linked to mitochondrial dysfunction which lacks comprehensive genetic insights. This study aims to investigate mitochondrial-related genes associated with chronic fatigue and explores therapeutic targets. We conducted summary-data-based Mendelian randomization (SMR) and Bayesian colocalization analyses using blood eQTL data (n = 31,684) and fatigue GWAS data (n = 449,019). Mitochondrial-related genes were sourced from MitoCarta3.0. Two-sample Mendelian randomization (TSMR) analysis and gene expression detection in rat models of fatigue were employed to enhance the robustness of our findings. Drug-gene interactions were screened via Drug SIGnatures (DSigDB) database and DrugBank database, followed by molecular docking and phenome-wide association study (PheWAS) for safety and pleiotropic effects evaluation. SMR identified nine mitochondrial-related genes, with AKAP10 (OR = 1.012) and MTHFD1L (OR = 1.027) showing robust colocalization and causal links to chronic fatigue. TSMR analysis also indicated significant causal relationships of AKAP10 (OR = 1.017, 95% CI = 1.011-1.023, p = 8.15e-08) and MTHFD1L (OR = 1.046, 95% CI = 1.002-1.091, p = 0.041) with chronic fatigue. Consistently, in fatigue model rats, the expression levels of Akap10 and Mthfd1l were significantly upregulated in both hippocampal and quadriceps tissues (p = 0.021, p = 0.003, p = 0.027, p = 0.001, respectively). Molecular docking revealed strong binding affinities (below -7.0 kcal/mol) between AKAP10, MTHFD1L and repurposed drugs (e.g., irinotecan, digoxin). PheWAS indicated that both AKAP10 and MTHFD1L exhibit no significant associations with other traits at the gene level. Mitochondria-related genes AKAP10 and MTHFD1L are promising targets for the treatment of chronic fatigue. Structural modification of existing drugs targeting these genes may lead to novel therapeutic approaches, which warrants further molecular and pharmacological validation to confirm their potential application in fatigue treatment.
- Open Access
- 14 October 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1545
The Effects and Mechanisms of Ti-Fu-Kang Decoction in Alleviating Central Fatigue: Insights from Network Pharmacology and Metabolomics
Background: Although Ti-Fu-Kang (TFK) decoction has been clinically used for fatigue management, the systematic understanding of its mechanisms, particularly against central fatigue, remains largely unknown. This study is the first to employ an integrative approach of network pharmacology and metabolomics to explore the mechanisms of TFK against central fatigue. Methods: The central fatigue rat model was established using the modified multiple platform method in conjunction with alternate-day fasting. Behavioral alterations were evaluated through six behavioral tests, while brain injury was assessed through HE and Nissl staining. Serum metabolic indicators were analyzed to identify fatigue-related metabolic disturbances. Western blot analysis was used to assess the protein phosphorylation level of PI3K and AKT1. Oxidative stress was assessed by measuring superoxide dismutase, malondialdehyde, and glutathione peroxidase activities. Network pharmacology and serum metabolomics investigated the molecular mechanisms and metabolic pathways. Results: TFK significantly ameliorated behavioral abnormalities and brain pathological damage in central fatigue model rats. Network pharmacology analysis and in vivo experiment revealed that TFK may mediate biological processes such as oxidative stress and neuron death via the PI3K-AKT signaling pathway. Moreover, analysis of serum fatigue-related metabolic indicators indicated that TFK significantly modulated metabolic disruptions by elevating the levels of glucose, liver glycogen, and muscle glycogen and reducing the levels of alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatine kinase, lactate, and lactate dehydrogenase in central fatigue rats. Serum metabolomics analysis revealed that TFK ameliorates central fatigue by modulating amino acid metabolism, specifically by altering the levels of leucine and L-tryptophan, which subsequently contributes to the restoration of 5-hydroxytryptamine and dopamine homeostasis. Conclusions: This study elucidates the potential therapeutic mechanism of TKF in alleviating central fatigue, providing a scientific and theoretical basis for broader application and development of TFK.
- 14 October 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1545
Open AccessThe Effects and Mechanisms of Ti-Fu-Kang Decoction in Alleviating Central Fatigue: Insights from Network Pharmacology and Metabolomics
Background: Although Ti-Fu-Kang (TFK) decoction has been clinically used for fatigue management, the systematic understanding of its mechanisms, particularly against central fatigue, remains largely unknown. This study is the first to employ an integrative approach of network pharmacology and metabolomics to explore the mechanisms of TFK against central fatigue. Methods: The central fatigue rat model was established using the modified multiple platform method in conjunction with alternate-day fasting. Behavioral alterations were evaluated through six behavioral tests, while brain injury was assessed through HE and Nissl staining. Serum metabolic indicators were analyzed to identify fatigue-related metabolic disturbances. Western blot analysis was used to assess the protein phosphorylation level of PI3K and AKT1. Oxidative stress was assessed by measuring superoxide dismutase, malondialdehyde, and glutathione peroxidase activities. Network pharmacology and serum metabolomics investigated the molecular mechanisms and metabolic pathways. Results: TFK significantly ameliorated behavioral abnormalities and brain pathological damage in central fatigue model rats. Network pharmacology analysis and in vivo experiment revealed that TFK may mediate biological processes such as oxidative stress and neuron death via the PI3K-AKT signaling pathway. Moreover, analysis of serum fatigue-related metabolic indicators indicated that TFK significantly modulated metabolic disruptions by elevating the levels of glucose, liver glycogen, and muscle glycogen and reducing the levels of alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatine kinase, lactate, and lactate dehydrogenase in central fatigue rats. Serum metabolomics analysis revealed that TFK ameliorates central fatigue by modulating amino acid metabolism, specifically by altering the levels of leucine and L-tryptophan, which subsequently contributes to the restoration of 5-hydroxytryptamine and dopamine homeostasis. Conclusions: This study elucidates the potential therapeutic mechanism of TKF in alleviating central fatigue, providing a scientific and theoretical basis for broader application and development of TFK.
- Open Access
- 21 February 2025
- Published by Elsevier in Pharmacological Research
- Vol. 213, 107671
Decoding TGR5: A comprehensive review of its impact on cerebral diseases
- 21 February 2025
- Published by Elsevier in Pharmacological Research
- Vol. 213, 107671
Open AccessDecoding TGR5: A comprehensive review of its impact on cerebral diseases